Immunic financials
$8.91−6.31%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$103.2M | -$98.1M | -$99.2M | -$119.5M | -$91.7M | -$49.0M | -$37.0M |
| Net income | -$97.2M | -$100.5M | -$93.6M | -$120.4M | -$92.9M | -$44.0M | -$34.9M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-6.20 | $-10.00 | $-21.10 | $-37.80 | $-39.30 | $-28.10 | $-45.20 |
| EBITDA | -$103.1M | -$97.9M | -$99.1M | -$86.4M | -$91.6M | -$48.9M | -$37.0M |
| Operating cash flow | -$85.8M | -$84.8M | -$70.8M | -$65.1M | -$83.2M | -$46.1M | -$28.5M |
| Free cash flow | -$86.0M | -$85.0M | -$71.2M | -$65.3M | -$83.3M | -$46.3M | -$28.6M |
| Diluted shares | 15.6M | 10.0M | 4.4M | 3.2M | 2.4M | 1.6M | 0.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.5M | $35.7M | $46.7M | $106.7M | $86.9M | $127.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $9.6M | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $24.1M | $40.9M | $54.3M | $127.8M | $139.1M | $167.9M |
| Total liabilities | $30.7M | $22.4M | $25.4M | $14.1M | $12.0M | $9.1M |
| Shareholders' equity | -$6.7M | $18.4M | $28.9M | $113.7M | $127.1M | $158.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology